No trial has ever tested oral GLP-1 compounds. So why are they the most expensive option?

Every efficacy figure you have seen for these drugs came out of a needle. Not one came out of a tablet.

The claim, and the evidence behind it

Orally disintegrating tablets are marketed as the needle-free path to the same results. Provider pages cite the familiar numbers — 20.9% in SURMOUNT-1, 14.9% in STEP 1 — alongside a product that dissolves under your tongue.

Those numbers were produced by a subcutaneous injection of an FDA-approved product. Every one of them. There is no ODT arm in SURMOUNT. There is no ODT arm in STEP. There is no published trial of a compounded ODT of either molecule at any dose.

Every row is an injection. There is no ODT row because there is no ODT trial.

Why the dosage form is not a detail

Semaglutide and tirzepatide are peptides — large, fragile molecules. The gut is specifically designed to dismantle molecules like them, and the oral mucosa is not built to absorb them. This is not a theoretical concern; it is the central pharmacological problem of oral peptide delivery, and solving it is hard enough that Novo needed a specific absorption enhancer and a dedicated development programme to get an approved oral semaglutide to market at all.

Bioavailability, peak concentration, half-life, total exposure — all of these can differ enormously between an injection and a tablet. For a compounded ODT, none of them have been published. Nobody has shown you how much drug reaches your bloodstream, because nobody has measured it in public.

That does not prove ODT does not work. It means nobody has shown that it does.

And it costs more

Here is the part that should stop you. At NexLife — whose full pricing matrix we hold and publish — the ODT is the most expensive form of both molecules.

You pay a premium of $13 to $20 a month — and you receive a product with no trial evidence behind its dosage form. That is an unusual thing to buy.

The one good reason to choose it

There is exactly one, and it is legitimate: you will not inject.

Needle phobia is real, and a treatment a patient will actually take can beat a better-evidenced treatment they will refuse. A clinician can reasonably support that trade. If you have tried to self-inject and cannot, an ODT is a defensible choice and you should not feel talked out of it.

What it is not is a cheaper option, a more effective option, or an equivalent option. If a provider implies any of those three, they are selling past the evidence.

What to ask

1. What is the bioavailability of this specific formulation, and where is that published?
2. Is there any pharmacokinetic data for this product at all?
3. What dose am I getting, and how does it compare to the injectable dose it replaces?
4. Why does it cost more than the injection if it has less evidence?

If the answer to question 1 or 2 cites SURMOUNT or STEP, the question has not been answered — those are injection trials. A provider who says plainly 'we don't have that data' is being more honest with you than one who reaches for the trial numbers.

Limitations of this analysis

Every page on this site should tell you where it stops being reliable. This one stops here.

Prices decay quickly. This is the fastest-moving data we publish. Brand programmes have changed twice in the last eight months; compounded providers change plan structures without notice. Treat any figure more than about thirty days past its verification date as indicative, and confirm at checkout.

Competitor pricing is reported, not captured by us. We hold dated captures for brand pricing and for NexLife. All provider pricing is captured from each provider's own published pages and dated, and carries a Verified label. Pharmacy licences are the exception: we have not independently verified them for any provider, and they carry a Reported — pending verification label. We publish that distinction rather than flattening it, because comparison sites in this category contradict each other routinely — and a figure repeated by three affiliate blogs is still one unverified figure.

We have not audited pharmacy licences. Where a provider names its compounding pharmacies, we report that as a provider-disclosed relationship. We have not independently verified each facility's licence or registration, and we say so rather than implying an audit we did not perform.

Advertised availability is not your availability. Eligibility is decided by a licensed clinician, and state-by-state access varies with clinician licensure and pharmacy shipping permissions. No page can promise you a price you will actually be offered.

We are commercially funded. The publisher and certain principals have financial relationships with some of the providers listed here, and we may earn a commission from provider links. That is disclosed in the footer of every page. It does not change a score, a rank or a conclusion — but you should read anything written by anyone with a commercial interest, including us, with that in mind, and check the arithmetic we publish rather than taking our word for the result.

Update history